Fields, K. K., Elfenbein, G. J., Saleh, R. A., Zorsky, P. E., Janssen, W. E., Perkins, J. B., … Machak, M. C. (1992). Ifosfamide, carboplatin, and etoposide in combination for induction and high-dose chemotherapy: focus on breast cancer and lymphoma. Hematol Oncol, 10(1), 61–74. https://doi.org/10.1002/hon.2900100111

Fields, K. K., G. J. Elfenbein, R. A. Saleh, P. E. Zorsky, W. E. Janssen, J. B. Perkins, T. G. Saleh, J. T. Piazza, L. E. Kronish, and M. C. Machak. “Ifosfamide, carboplatin, and etoposide in combination for induction and high-dose chemotherapy: focus on breast cancer and lymphoma.” Hematol Oncol 10, no. 1 (1992): 61–74. https://doi.org/10.1002/hon.2900100111.

Fields KK, Elfenbein GJ, Saleh RA, Zorsky PE, Janssen WE, Perkins JB, et al. Ifosfamide, carboplatin, and etoposide in combination for induction and high-dose chemotherapy: focus on breast cancer and lymphoma. Hematol Oncol. 1992;10(1):61–74.

Fields, K. K., et al. “Ifosfamide, carboplatin, and etoposide in combination for induction and high-dose chemotherapy: focus on breast cancer and lymphoma.” Hematol Oncol, vol. 10, no. 1, 1992, pp. 61–74. Pubmed, doi:10.1002/hon.2900100111.

Fields KK, Elfenbein GJ, Saleh RA, Zorsky PE, Janssen WE, Perkins JB, Saleh TG, Piazza JT, Kronish LE, Machak MC. Ifosfamide, carboplatin, and etoposide in combination for induction and high-dose chemotherapy: focus on breast cancer and lymphoma. Hematol Oncol. 1992;10(1):61–74.